CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma [Yahoo! Finance]
CureVac N.V. - Ordinary Shares (CVAC)
Company Research
Source: Yahoo! Finance
Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac's first investigational cancer vaccine based on its proprietary second-generation mRNA backbone. It encodes a single fusion protein comprising eight epitopes with demonstrated immunogenicity in glioblastoma. "After successful completion of the dose-escalation part A of this clinical study with CVGBM, the dose expansion part B is important to confirm that we have selected the appropriate dose based on safety and immunogenicity for further studies in patients suffering from glioblastom
Show less
Read more
Impact Snapshot
Event Time:
CVAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVAC alerts
High impacting CureVac N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CVAC
News
- CureVac (NASDAQ: CVAC) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $16.00 price target on the stock.MarketBeat
- CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress Accesswire
- CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program [Yahoo! Finance]Yahoo! Finance
- CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramAccesswire
- CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 CongressAccesswire
CVAC
Sec Filings
- 9/27/24 - Form 144
- 9/25/24 - Form 144
- 9/13/24 - Form 6-K
- CVAC's page on the SEC website